Physician profile
Scott Leiser
NPI 1457885584
$678.44
in general payments reported to CMS, 2019-2025
13 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $80.38 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $172.50 | 2025 | Airsupra |
| Exact Sciences Corporation | $79.49 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $74.18 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $72.29 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $56.74 | 2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $43.87 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.54 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $40.95 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $22.27 | 2024 | Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $20.93 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $18.43 | 2025 | Capvaxive, Gardasil 9 |
| Incyte Corporation | $18.23 | 2024 | Opzelura |
| Pfizer INC. | $16.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Leiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.